Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jul 9, 2021

Ocuphire’s VEGA-1 Phase 2 Trial in Presbyopia Meets Primary and Secondary Endpoints

Jun 30, 2021

Processa Pharmaceuticals Enters Into A Licensing Agreement With Ocuphire Pharma, Inc., For The Development Of RX-3117

Jun 17, 2021

Ocuphire Announces Addition to the Russell Microcap® Index

Jun 11, 2021

Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market

Jun 8, 2021

Ocuphire Announces Appointment of Jay S. Pepose, M.D., Ph.D. to Its Board of Directors

Jun 8, 2021

Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jun 4, 2021

Ocuphire to Host Key Opinion Leader Event on Nyxol® as a Potential New Treatment Option for Reversing Pharmacologically Induced Mydriasis

May 20, 2021

Ocuphire Granted Two New U.S. Patents Covering Late-Stage Drug Candidate Nyxol®, Including for the Treatment of Presbyopia

May 18, 2021

Ocuphire Completes Enrollment in VEGA-1 Phase 2 Clinical Trial Investigating Nyxol® in Combination with Low-Dose Pilocarpine for Treatment of Presbyopia

May 12, 2021